ClinicalTrials.gg
RecruitingNCT02611492GRAAPH2014Updated Oct 21, 2019

A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults

A Phase 3 interventional study of Nilotinib and Methotrexate in Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2019-10-21.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2020, 5 years 11 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
265
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Philadelphia Chromosome with a site in France — 2 open to participants now, 5 under way, 4 of them phase 3. Philadelphia Chromosome · France.

Planned enrollment
7th of 13
265 · median 265
Started
2016
with 1 other
Phase 3
5 of 14
1 open now
Registered
8th of 14
by date
Lead sponsor
3 of 14
Assistance Publique - Hôpitaux de Paris

Among the 14 studies in Philadelphia Chromosome with a site in France, this one is the 7th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2016, is one of 5 in phase 3, and was the 8th registered.

Philadelphia Chromosome

52 studies on the registry are indexed under Philadelphia Chromosome; 13 are open to participants now.

Browse Philadelphia Chromosome studies →

Open to participants now

2 of the 14 studies in Philadelphia Chromosome with a site in France are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 10 Philadelphia Chromosome studies recruiting now, 5 (50%) set no upper age limit and 5 (50%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years to 59 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Philadelphia Chromosome with a site in France, or all of them as a file.
02

Study summary

The Primary objective is to assess the non-inferiority of the experimental arm (arm B) compared to the control arm (arm A) in terms of Major Molecular Response (MMolR) after the 4th cycle (MRD4) in patients aged 18-59 years old with de novo Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL)

03

Conditions studied

  • Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia
04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patient

  1. Whose blood and bone marrow explorations have been completed before the prephase
  2. Aged 18-59 years old with newly-diagnosed non previously treated Ph+ ALL according to WHO 2008 criteria (confirmed diagnosis of the Philadelphia chromosome defined by the reciprocal translocation of chromosomes 9 and 22, t(9;22) and/or presence of the BCR-ABL molecular maker)
  3. With ≥ 20% bone marrow blasts
  4. With (ECOG) Performans Status ≤ 3
  5. With or without central nervous system (CNS) or testis involvement
  6. Without evolving cancer (except basal cell carcinoma of the skin or "in situ" carcinoma of the cervix) or its chemo- or radio-therapy should be finished at least since 6 months.
  7. Having received no previous treatment for this hematological disease (including IT injection)
  8. Having signed written
  9. With efficient for women of childbearing age (excluding estrogens and IUD)
  10. With health insurance coverage
  11. Who have received (or being receiving) the recommended steroid prephase.

Note 1: Secondary ALL (antecedent of chemo- or radio-therapy) can be included Note 2: In case of high vascular risk (see section "study management") the patient will not be able to receive nilotinib unless an ultra sound Doppler of the neck and lower limbs has been performed during the pre-phase and treatment validated by the medical coordinators of the protocol via the secretariat.

Exclusion criteria

Exclusion Criteria:

Patient:

  1. Previously treated with Tyrosine Kinase Inhibitor (TKI)
  2. With another active
  3. With general or visceral to intensive therapy (except if considered related to the ALL):

    1. (AST) and/or alanine aminotransferase (ALT) > 2.5 x (ULN)
    2. Total > 1.5 x ULN
    3. Creatinine > 1.5 x ULN or \<50 mL/mn
    4. Serum amylase or lipase > 1.5 x ULN or antecedents of acute pancreatitis
  4. With heart failure, including at least one of the following criteria:

    1. (LVEF) \<50% or below the lowest normal threshold, as determined by or heart failure ( grade III or IV)
    2. Impossibility to measure the on ECG
    3. Complete left bundle branch block
    4. Pacemaker
    5. Congenital long QT syndrome of known familial antecedents of long QT syndrome
    6. Antecedents or current ventricular or atrial tachyarrhythmia,
    7. Baseline bradycardia (\<50 bpm) clinically significant
    8. Corrected QT interval (QTc)> 450 msec established on the mean of 3 baseline ECG
    9. Antecedents of myocardial infarct in the past 6 months
    10. Instable angor within the past 12 months
    11. Any heart condition clinically significant (i.e. congestive heart failure, uncontrolled hypertension)
  5. Active uncontrolled infection, any other concurrent disease deemed to interfere with the conduct of the study as judged by the investigator
  6. Severe evolving infection, or known or Human T-Lymphotropic Virus type I (HTLV1) seropositivity, or active infection by or C virus
  7. Pregnant (beta-HCG) or nursing woman
  8. Women of not willing to use an effective form of during participation in the study and at least three months thereafter. Patient not willing to ensure not to beget a child during participation in the study and at least three months thereafter.
  9. Having received an treatment or participation in another trial within 30 days prior to entering this study.
  10. Not able to bear with the procedures or the frequency of visits planned in the trial.
  11. Unable to consent, under tutelage or curators, or judiciary safeguard
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
265 participants (estimated)

Study arms

  • Active comparator
    Intensive Arm (A)

    4 cycles + 2 interphases +Hematopoietic Stem Cell Transplantation (SCT) + Post-SCT Maintenance

    Drug: Nilotinib · Drug: Methotrexate · Drug: Aracytine (Ara C) · Drug: Granulocyte Colony-Stimulating Factor (G-CSF) · Drug: Depomedrol · Drug: Dexamethasone · Drug: Vincristine · Drug: Imatinib · Drug: 6 Mercaptopurine (6MP)

  • Experimental
    Light Arm (B)

    4 cycles + 2 interphases +Hematopoietic Stem Cell Transplantation (SCT) + Post-SCT Maintenance

    Drug: Nilotinib · Drug: Methotrexate · Drug: Granulocyte Colony-Stimulating Factor (G-CSF) · Drug: Depomedrol · Drug: Dexamethasone · Drug: Vincristine · Drug: Imatinib · Drug: 6 Mercaptopurine (6MP)

Interventions

06

What researchers measure

Primary outcomes

  1. Major Molecular Response (MMolR)

    defined as a breakpoint cluster region (BCR)-Abelson (ABL) ratio \< 0.1% in the bone marrow sample of MRD4

    Time frame: 4 cycles (4 months)

Secondary outcomes

  1. Complete remission after cycle 1

    Time frame: day 28

  2. Cumulative incidence of treatment- and transplantation-related mortality

    Time frame: 2 years

  3. Cumulative incidence of relapse

    Time frame: 10 years

  4. Relapse free survival

    Time frame: 10 years

  5. Event-free survival

    Time frame: 10 years

  6. overall survival

    Time frame: 10 years

  7. T315I mutation

    mutations will be assessed by Reverse transcription Quantitative Polymerase Chain Reaction (RQ-PCR) sequencing in case of progression or relapse

    Time frame: 10 years

  8. Toxicity

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2016, a primary completion of Dec 2020 and a completion of Dec 2025. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2015
First posted
Nov 20, 2015
Start
Apr 2016
Primary completionEst.
Dec 2020
CompletionEst.
Dec 2025
Last update
Oct 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02611492
Responsible party
Sponsor
First posted
Nov 20, 2015
Start date
Apr 2016
Primary completion
Dec 2020 (estimated)
Completion
Dec 2025 (estimated)
Last update
Oct 21, 2019

Study contacts

Hervé Dombret, MDPhD
Contact
herve.dombret@aphp.fr
+33 (0)1 57 27 68 47
Véronique Lhéritier
Contact
veronique.lheritier@chu-lyon.fr
+33(0)4 78 86 22 39

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion